Arrowhead Pharmaceuticals Launches Expanded Access Program for Plozasiran
Arrowhead Pharmaceuticals, Inc. has launched an Expanded Access Program (EAP) to offer plozasiran, its investigational therapy, to patients with...
Jon Napitupulu
Actylis and Novo Nordisk Pharmatech Form Strategic Partnership for Benzalkonium Chloride Distribution in Europe
Actylis and Novo Nordisk Pharmatech A/S have partnered to distribute pharmaceutical-grade Benzalkonium Chloride (BKC) in key European markets, including...
Verge Genomics and Ferrer to Co-develop ALS Therapy VRG50635
Verge Genomics and Ferrer have embarked on a strategic partnership to advance the development and potential commercialization of VRG50635,...
Gilead Sciences Successfully Acquires CymaBay
Gilead Sciences, Inc. has finalized its acquisition of CymaBay Therapeutics, Inc. for an approximate total equity value of $4.3...
FDA Grants Expanded Labels for Esperion’s Nexletol® and Nexlizet®
Esperion has announced a pivotal development in cardiovascular treatment, with the FDA approving broad label expansions for NEXLETOL® (bempedoic...
LIB Therapeutics & Hasten Biopharmaceuticals’ Lerodalcibep Trial Approved in China
LIB Therapeutics, Inc. (LIB), a pioneering biopharmaceutical company, has made considerable progress with its cholesterol-lowering drug, Lerodalcibep and designed...
Digital Biomarkers Market 2024-2029: Virtual Research & Mental Health Applications Drive Growth
The “Global Digital Biomarkers Market – Outlook & Forecast 2024-2029” report showcases the rapidly expanding digital biomarkers market, which...
eGenesis Achieves Breakthrough: First Successful Transplant of Genetically Engineered Porcine Kidney
eGenesis, a pioneering biotechnology company, has announced a groundbreaking advancement in transplantation with the successful transplantation of a genetically...
BMS’s Checkmate-9DW Trial Shows Opdivo Plus Yervoy Efficacy in Advanced Hepatocellular Carcinoma
Bristol Myers Squibb (BMY) has revealed positive outcomes from the Phase 3 CheckMate -9DW clinical trial, showcasing the effectiveness...
Tevogen Bio’s Investigational T Cell Therapy Effective Against JN.1 Variant
Tevogen Bio Holdings announced the enduring efficacy of its investigational COVID-19 treatment, TVGN 489, against the latest dominant SARS-CoV-2...